News

Recruitment Reopened for Phase 3 AFFINE Gene Therapy Trial

Industry News & Research

This trial is evaluating the efficacy and safety of a single infusion of an investigational gene therapy in individuals with moderately severe…

Read More

BioMarin Shares Community Update for Valoctocogene Roxaparvovec

Industry News & Research

Biomarin recently provided an “Update for the Hemophilia Community,” on the ongoing clinical trial program for its investigational hemophilia A gene therapy,…

Read More

Statement from Patient Groups in Response to Court Ruling on Cost-Free Coverage of Preventive Health Services

Industry News & Research, Living with a Bleeding Disorder

HFA and 25 other patient groups issued the following statement in response to Wednesday’s court ruling in Braidwood v. Becerra (a lawsuit formerly known…

Read More

Rare Factor X Deficiency Survey Shows Disparity in Care

Industry News & Research

Initial data from the survey were presented at the recent Thrombosis and Hemostasis Summit of North America and NHF’s Bleeding Disorders Conference…

Read More

FDA Grants Priority Review for Sanofi’s BIVV001

Industry News & Research

BIVV001 is a recombinant factor VIII therapy (rFVIII) developed for the prevention of bleeding episodes in hemophilia A patients via once weekly…

Read More

von Willebrand Disease (VWD) and Iron Deficiecy – Speaker: Bethany Samuelson, M.D.

Health and Well Being, Industry News & Research, Living with a Bleeding Disorder

In this video, Dr. Bethany Samuelson Bannow, of Oregon Health & Science University, discusses the role of iron in the body, the…

Read More

Gene Therapy and Bleeding Disorders: Making Sense of It All

Health and Well Being, Industry News & Research

Gene Therapy is definitely a dominant topic in the bleeding disorders community, with new articles being published regularly. Read some of the…

Read More

Supreme Court Decision and Genetic Testing

Health and Well Being, Industry News & Research

by: Laurie Kelley Thoughts on how the Supreme Court decision on abortion might affect genetic testing outcomes. Read more here. The recent…

Read More

Does Gene Therapy Face Uphill Battle? Gene Therapies for Hemophilia Treatment Will Face Strong Market Headwinds, Research Suggests

Industry News & Research

Solid market position of Hemlibra and strong prescriber interest in RNAi and TFPI treatment options, combined with patient concerns regarding gene therapies,…

Read More

Gene Therapy and Bleeding Disorders: Where Are We Now, and What’s on the Horizon?

Industry News & Research

The National Hemophilia Foundation’s 16th Workshop on Novel Technologies and Gene Transfer for Hemophilia, held in November, addressed these questions and more….

Read More

Hemophilia B— An Excellent Candidate for Gene Therapy

Industry News & Research

Current hemophilia B treatments offer strong protection from bleeds, but impact patient lifestyle and require consistent infusions to keep protection levels high.1…

Read More

Making Sense of It All – Gene Therapy

Industry News & Research

What exactly is a gene? What happens when genes mutate? And can gene therapy research help solve problems related to mutations? Learn…

Read More

Paper Features Q&A Resource on Shared Decision Making and Gene Therapy

Industry News & Research

The Q&A resource highlighted here is meant to encompass all stages of a patient’s decision making journey in gene therapy. As investigational…

Read More

BioMarin Presents Abstract on Vector DNA Transmission Risk at ISTH

Industry News & Research

The focus of the abstract is the investigational hemophilia A gene therapy, valoctocogene roxaparvovec. BioMarin recently shared findings from a phase 3…

Read More

The High Cost of Hemophilia

Advocacy & Legislation, Health and Well Being, Industry News & Research

Just one bleed in people with severe hemophilia A receiving prophylaxis has the potential to negatively affect health-related quality of life, and raise…

Read More

Prophylactic Therapy for Glanzmann Thrombasthenia Moves Towards Clinical Trials

Industry News & Research

Glanzmann Thrombasthenia is an ultra-rare inherited bleeding disorder that is characterized by poorly functioning platelets. The recent Congress of the International Society…

Read More

Sanofi Provides Fitusiran Trial Updates at ISTH

Industry News & Research

These updates were presented during the International Society on Thrombosis and Haemostasis (ISTH) Congress in London. Sanofi recently shared new clinical trial…

Read More

Novel Pilot Program to Focus on Genetic Diseases and Precision Medicine

Industry News & Research

A newly launched program is designed to advance a diagnostic and precision medicine approach in newborns. The Rady Children’s Institute for Genomic…

Read More

NHF Requests Risk Evaluation and Mitigation Strategy for Pending Gene Therapy Treatments

Industry News & Research

Read a citizen’s petition that was formally submitted to the Food and Drug Administration by NHF. On July 1, the National Hemophilia…

Read More

New Genotyping Recommendations Issued by MASAC

Industry News & Research

The new recommendation describes the proven benefits of genotyping people with hemophilia NHF’s Medical and Scientific Advisory Council (MASAC) has approved a…

Read More

Diabetes Risk in Hemophilia vs Unaffected Groups Compared in Retrospective Study

Industry News & Research, Living with a Bleeding Disorder

The hemophilia data for this study was drawn from de-identified medical records from four North American hemophilia treatment centers. The U.S. diabetes…

Read More

Bayer Announces Discontinuation of Kogenate® FS

Industry News & Research

Kogenate® was first approved by the U.S. Food and Drug Administration in 1993. Bayer has announced that they are discontinuing the recombinant…

Read More

FDA Grants Breakthrough Status to BIVV001

Industry News & Research

BIVV001 is an investigational recombinant factor VIII therapy (rFVIII) developed for the prevention of bleeding episodes in hemophilia A patients via once…

Read More

BioMarin Announces Delay in Application to FDA

Industry News & Research

Roctavian is Biomarin’s investigational hemophilia A gene therapy, which is currently in multiple ongoing clinical trials. BioMarin recently announced that their planned…

Read More